
IDWeek 2022 Poster #P2036

D al VIM-Prod cing *Proteus mirabilis*, Incl ding a No el VIM-75, Among Elderl Patient in a Medical Center from H ngar: Report from the 2020 SENTRY Antimicrobial S r eillance Program


Lalitaga ri M. De hpande¹, Katalin B rian², Ilona D c i C an i², Mariana Ca tanheira¹ ¹ JMI Laboratories, North Liberty, IA, USA; ² Albert Szent-Györgyi Medical Centre, Szeged, Hungary

Materials and Methods

- A total of 16 . 🗘 🂢 isolates were received from Hungary during 2020 as part of the SENTRY Antimicrobial Surveillance Program.
- Isolates were susceptibility tested by reference broth microdilution as described by the Clinical and Laboratory Standards Institute (CLSI) M07 (2018) and M100 (2022) documents.
- Quality control (QC) was performed according to the CLSI M100 (2022) criteria.
- Carbapenem-nonsusceptible isolates were submitted to whole genome sequencing and analysis.
- Total genomic DNA was used as input material for library



Mariana Castanheira Chief Scientific Officer, JMI Laboratories 345 Beaver Kreek Center, Suite A North Liberty, Iowa 52317 USA mariana-castanheira@jmilabs.com



To obtain a PDF of this visit https://www.jmi labs.com/data/posters /IDWeek2022_DualVIM No personal information

is stored.